A Dual-Antigen SARS-CoV-2 Serological Assay Reflects Antibody Avidity

Nakagama, Yu; Nitahara, Yuko; Kaku, Natsuko; Tshibangu‐Kabamba, Evariste; Kido, Yasutoshi

doi:10.1128/jcm.02262-21

Cited by 23 publications

(14 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The third limitation is that the anti-S antibody data were capped at 2500 IU/mL because of the relative lack of linearity of the used technique above this level. The use of a double antigen-sandwich method (Roche Elecsys immunoassays) could also be a limitation since a recent study showed that the avidity of the SARS-CoV-2 antibodies could affect the results with this type of assay [ 37 ]. Another limitation is the small number of subjects in which cellular immune response was studied.…”

Section: Discussionmentioning

confidence: 99%

Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa)

et al. 2022

View full text Add to dashboard Cite

Background: The mass vaccination campaign against SARS-CoV-2 was started in Tunisia on 13 March 2021 by using progressively seven different vaccines approved for emergency use. Herein, we aimed to evaluate the humoral and cellular immunity in subjects aged 40 years and over who received one of the following two-dose regimen vaccines against SARS-CoV-2, namely mRNA-1273 or Spikevax (Moderna), BNT162B2 or Comirnaty (Pfizer-BioNTech), Gam-COVID-Vac or Sputnik V (Gamaleya Research Institute), ChAdOx1-S or Vaxzevria (AstraZeneca), BIBP (Sinopharm), and Coronavac (Sinovac). Material and methods: For each type of vaccine, a sample of subjects aged 40 and over was randomly selected from the national platform for monitoring COVID-19 vaccination and contacted to participate to this study. All consenting participants were sampled for peripheral blood at 3–7 weeks after the second vaccine dose to perform anti-S and anti-N serology by the Elecsys® (Lenexa, KS, USA) anti-SARS-CoV-2 assays (Roche® Basel, Switzerland). The CD4 and CD8 T cell responses were evaluated by the QuantiFERON® SARS-CoV-2 (Qiagen® Basel, Switzerland) for a randomly selected sub-group. Results: A total of 501 people consented to the study and, of them, 133 were included for the cellular response investigations. Both humoral and cellular immune responses against SARS-CoV-2 antigens differed significantly between all tested groups. RNA vaccines induced the highest levels of humoral and cellular anti-S responses followed by adenovirus vaccines and then by inactivated vaccines. Vaccines from the same platform induced similar levels of specific anti-S immune responses except in the case of the Sputnik V and the AstraZeneca vaccine, which exhibited contrasting effects on humoral and cellular responses. When analyses were performed in subjects with negative anti-N antibodies, results were similar to those obtained within the total cohort, except for the Moderna vaccine, which gave a better cellular immune response than the Pfizer vaccine and RNA vaccines, which induced similar cellular immune responses to those of adenovirus vaccines. Conclusion: Collectively, our data confirmed the superiority of the RNA-based COVID-19 vaccines, in particular that of Moderna, for both humoral and cellular immunogenicity. Our results comparing between different vaccine platforms in a similar population are of great importance since they may help decision makers to adopt the best strategy for further national vaccination programs.

show abstract

Section: Discussionmentioning

confidence: 99%

Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa)

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The time interval and the administration of additional doses of vaccine enhances the maturity of elicited antibodies and increases their avidity toward targeting antigens [30] . The Elecsys platform is more likely to detect antibodies with higher avidity [31] . In SARS-CoV-2-naïve individuals, a single dose of mRNA vaccine generates antibodies of incomplete maturity, and high-affinity antibodies are only elicited after the second dose [32] .…”

Section: Discussionmentioning

confidence: 99%

Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan

Matsuura

Fukushima

Nakagama

et al. 2022

Vaccine

Self Cite

View full text Add to dashboard Cite

“…Nakagama et al [ 23 ] followed the convalescent phase of patients with COVID-19, measuring anti-RBD antibody titers using Elecsys ® Anti-SARS-CoV-2S (anti-RBD total Ig; Roche) and ARCHITECT SARS-CoV-2 IgG II Quantitative (Abbott) and indicated that the antibody titers measured by the Roche system were high avidity indices, and persisted even in the late convalescent period. Matusali et al [ 24 ] investigated the dynamic association among binding and functional antibodies in healthcare workers receiving the BNT162b2 mRNA COVID-19 vaccine.…”

Section: Discussionmentioning

confidence: 99%

Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study

et al. 2022

View full text Add to dashboard Cite

Vaccines against SARS-CoV-2 with good efficacy are now available worldwide. However, gained immunity diminishes over time. Here, we investigate the course of both humoral and cell-mediated immunity in response to three doses of the Pfizer mRNA BNT162b2 SARS-CoV-2 vaccine in healthcare workers in Japan. SARS-CoV-2 anti-receptor-binding domain (RBD) antibodies (total Ig, IgG), neutralizing antibodies (NAb), and ELISpot were measured in serum and whole blood samples collected after each vaccine dose. ELISpot numbers were higher than the cutoff values in most participants at all times. It was suggested that the difference in behavior between humoral immunity and cell-mediated immunity with age is complementary. Anti-RBD total Ig, IgG, and NAb indicated a high correlation at each time point after vaccine doses. Total Ig was retained long-term after the second dose and increased significantly faster by the booster dose than IgG. Nab levels of all subjects were ≤20% six months after the second dose, and the correlation coefficient was greatly reduced. These are due to the avidity of each antibody and differences among commercial kits, which may affect the evaluation of immunokinetics in previous COVID-19 studies. Therefore, it is necessary to harmonize reagents categorized by the same characteristics.

show abstract

A Dual-Antigen SARS-CoV-2 Serological Assay Reflects Antibody Avidity

Abstract: Serial antibody measurements using an array of SARS-CoV-2 immunoassays have demonstrated differing kinetics among assay platforms (1).…

Cited by 23 publications

References 3 publications

Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa)

Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa)

Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan

Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study

Contact Info

Product

Resources

About